Biodesix Appoints Jean Franchi and Hany Massarany to the Company's Board of Directors
July 27, 2020 at 04:56 pm IST
Share
Biodesix reported the appointment of Jean Franchi and Hany Massarany to the company's board of directors. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Massarany has extensive experience in the global diagnostics industry, with expertise in molecular diagnostic testing. Franchi currently serves as chief financial officer for Replimune Group, Inc. Massarany served as president and chief executive officer of GenMark Diagnostics, Inc. from 2011 to 2020. Prior to joining GenMark, he held the role of president at Ventana Medical Systems and head of Roche Tissue Diagnostics.
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
BIODESIX, INC. 
